---
title: "Will the FDA approve intismeran autogene (V940/mRNA-4157)? — intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma"
canonical_url: https://betcrypto.now/events/will-the-fda-approve-intismeran-autogene-v940mrna-4157-intismeran-autogene-v940mrna-4157-with-pembrolizumab-keytruda-for-adjuvant-treatment-of-completely-resected-stage-iib-iv-melanoma
status: live
trading_closes_at: 2028-07-01T03:59:00+00:00
total_volume_usd: 2000.93
venues: ["Kalshi"]
categories: []
prices_as_of: 2026-10-09T05:18:04+00:00
publisher: BetCrypto
data_api: https://betcrypto.now/api/v1/events/will-the-fda-approve-intismeran-autogene-v940mrna-4157-intismeran-autogene-v940mrna-4157-with-pembrolizumab-keytruda-for-adjuvant-treatment-of-completely-resected-stage-iib-iv-melanoma
---

# Will the FDA approve intismeran autogene (V940/mRNA-4157)? — intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma

Live · $2,001 traded · listed on Kalshi

## Main market

| Outcome | Probability | Cheapest | Kalshi |
|---|---|---|---|
| Before Jan 1, 2028 | 77% | 81¢ on Kalshi | 81¢ |
| Before Oct 1, 2027 | 60% | 64¢ on Kalshi | 64¢ |
| Before Jul 1, 2028 | — | — | — |
| Before Jul 1, 2027 | — | — | — |
| Before Apr 1, 2027 | — | — | — |

## Open on a venue

- [Kalshi](https://betcrypto.now/go/e/304218?via=md)

---

Probability is the cross-venue consensus (book midpoints, 0–100%). Venue columns are what buying costs there (the ask). Prices move constantly; re-check at the canonical URL or https://betcrypto.now/api/v1/events/will-the-fda-approve-intismeran-autogene-v940mrna-4157-intismeran-autogene-v940mrna-4157-with-pembrolizumab-keytruda-for-adjuvant-treatment-of-completely-resected-stage-iib-iv-melanoma.

BetCrypto is an odds-comparison and information service. It accepts no wagers and gives no betting or financial advice; prediction-market availability depends on where you live.